(Q42721094)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

10

Steven E Nissen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

7

John J P Kastelein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Christie M. Ballantyne

4

object named as

Christie M Ballantyne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Allan Gordon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Jan Johannson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Philip J Barter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

H Bryan Brewer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Norman C Wong

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Marilyn R N Borgman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular Drugs and Therapy

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

181-187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Antiinflammatory properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of the amount and intensity of exercise on plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Effect of ACAT inhibition on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6373-5

10.1007/S10557-012-6373-5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22349989%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference